Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2022 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Revolution Medicines Third Quarter 2022 Earnings Webcast.
Source: insidermonkey.com
📰 Phase Ib Codebreak News
Phase Ib Codebreak News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Phase Ib Codebreak. Real-time updates on events, politics, business and more.
Despite Slowing Disease Progression, Amgen's Lung Cancer Studies Show High Liver Toxicity
Results from two Amgen studies on Lumakras for lung cancer showed its ability to slow disease progression, although combining it with immunotherapy increased the risk for TRAEs.
Source: biospace.com
Amgen reveals new combination data for KRAS inhibitor
Phase Ib CodeBreaK study evaluated Lumakras in over ten different investigational combination regimens - News - PharmaTimes
Source: pharmatimes.com